PTTG Binding Factor (PBF or PTTG1IP) is a little characterised proto-oncogene that has been implicated in the etiology of breast and thyroid tumors. In this study, we created a murine transgenic model to target PBF expression to the thyroid gland (PBF-Tg mice) and found that these mice exhibited normal thyroid function but a striking enlargement of the thyroid gland associated with hyperplastic and macrofollicular lesions. Expression of the sodium iodide symporter (NIS), a gene essential to the radioiodine ablation of thyroid hyperplasia, neoplasia and metastasis, was also potently inhibited in PBF-Tg mice. Critically, iodide uptake was repressed in primary thyroid cultures from PBF-Tg mice, which could be rescued by PBF depletion. PBF-Tg thyroids exhibited upregulation of Akt and the TSH receptor (TSHR), each known regulators of thyrocyte proliferation, along with upregulation of the downstream proliferative marker cyclin D1. We extended and confirmed findings from the mouse model by examining PBF expression in human multinodular goitres (MNG), a hyperproliferative thyroid disorder, where PBF and TSHR was strongly upregulated relative to normal thyroid tissue. Further, we showed that depleting PBF in human primary thyrocytes was sufficient to increase radioiodine uptake. Together, our findings indicate that overexpression of PBF causes thyroid cell proliferation, macrofollicular lesions and hyperplasia, as well as repression of the critical therapeutic route for radioiodide uptake.
Introduction
Described in only eleven publications (1-11) Pituitary Tumor Transforming Gene binding factor (PBF) was identified through its ability to interact with PTTG1, the human securin (3) . PBF comprises 6 exons spanning 24 Kb within chromosomal region 21q22.3. The 180 amino acid peptide sequence of PBF shares no significant homology with other human proteins, but is highly conserved across a wide diversity of animal species (73% homology to mouse, 67% frog, 60% chicken, 52% zebra fish), suggesting both unique function and significant evolutionary importance. PBF is widely expressed in normal human tissues, including normal thyroid (3, 10) . Whilst expression is low in normal breast tissue, immunohistochemical analysis demonstrated that PBF was strongly expressed in epithelial cells of all types and grades of breast tumour assessed (11) .
Initial protein prediction studies suggested that PBF was a cell surface glycoprotein due to a potential N-terminal signal peptide, transmembrane domain, endocytosis motif and two putative N-glycosylation sites (10) . PBF also possesses an extracellular N-terminal cysteine-rich region, similar to that found in the membrane-associated plexins, semaphorins and integrins (12) . In contrast to evidence supporting the characterisation of PBF as a membrane protein, the presence of a bipartite nuclear localisation signal (NLS) near the C-terminus suggested PBF may also be a nuclear protein (3).
We previously characterised PBF expression in thyroid cancers, and demonstrated it to be a transforming gene in vitro, and to be tumourigenic in vivo (8) . Furthermore, high PBF expression was independently associated with poor prognosis in human differentiated thyroid cancer. Most recently, we showed that PBF represses iodide uptake in thyroid cells in vitro, both through transcriptional regulation (2) and altered subcellular trafficking (6) of the sodium iodide symporter (NIS). Outside the thyroid, we recently described a role for PBF in the aetiology of breast cancer (11) , and defined PBF function in a mouse model of Downs' Syndrome angiogenesis (5) .
PBF is thus a relatively uncharacterised protein implicated in multiple cellular processes, particularly in the setting of endocrine neoplasia. However, the precise function of PBF in vivo, and the oncogenic potential of PBF within a specific organ, has not been tested. Whilst subcutaneous injection of stable NIH3T3 lines overexpressing PBF elicited large and aggressive tumours in nude mice (8) , a more physiological appraisal of tumour induction is lacking. Thus, to investigate the 4 function of PBF in vivo, we generated a murine transgenic model of PBF expression (PBF-Tg) targeted to the thyroid gland. We now present extensive data suggesting that PBF regulates thyroid gland growth through increased cell proliferation, an effect that is independent of thyroid function and growth factor induction, and induces significant hyperplasia. Furthermore, we propose that PBF represents a gene of direct clinical relevance to thyroid hyperplasia and neoplasia, given that it is over-expressed in human MNG and potently represses iodide uptake in vivo. 
Methods

Generation of PBF-Tg transgenic mice
WT and transgenic PBF-Tg mice were bred at the University of Birmingham and all experiments performed in accordance with U.K. Home Office regulations. The generation of the PBF-Tg transgenic line was performed by microinjection of fertilized mouse oocytes with the Tg-PBF-HA transgene and subsequent transfer into pseudopregnant females, as per standard protocols (13) (14) . Further details on construction of the Tg-PBF-HA transgene are provided in Supplementary Fig. S1 .
Transgene copy number was determined by real-time RT-PCR essentially as described previously (15) . Primers used to detect the human PBF gene were 5'- 
RNA extraction, reverse transcription quantitative PCR and Western blot analysis
Total RNA was extracted from mouse thyroids using the RNeasy Micro Kit (Qiagen) and reverse transcribed using the Reverse Transcription System (Promega), as previously described (2) . Expression of specific mRNAs was determined using 7500 Real-time PCR system (Applied Biosystems; ref (16) ). Western blot analysis was performed as we have described previously (1, 6, 17) . After blocking Western gels were probed with specific antibodies against TSHR (H-155), (Santa Cruz Biotechnology), 1:500; TSHR (2C11), (AbD Serotec), 1:200; phospho-Akt (Ser473) (D9E) XP (Cell Signalling Technology), 1:1000; total Akt, (Millipore), 1:1000 and PBF (6, 11), 1:1000.
Immunohistochemistry
Mouse thyroid specimens were immunostained with specific antibodies against cyclin D1, (Abcam), 1:100; HA, (Covance Research Products), 1:1000 and NIS, (Alpha Diagnostic Intl), 1:50 using protocols as described previously (8, 18) .
Immunostained sections were counterstained with Mayer's hematoxylin. For negative controls the primary antibody was replaced by 10% normal goat serum.
Analysis of thyroid morphology
Thyroid glands were removed from mice aged between 4 and 78 weeks using a dissecting microscope. H&E and immunostained thyroid tissue sections were viewed under a light-microscope (Zeiss) and images captured using Axiovision software (Version 4). The diameter of thyroid follicles (major axis) was measured using ImageJ software. A standard 100 μm scale bar (Axiovision) was used to convert pixels to μm.
Primary thyrocyte culture, siRNA transfection and iodide uptake assays
Primary thyrocyte cultures were performed as described previously (17, 19) . Seven days after seeding thyrocyte cultures were transfected with PBF-specific and control siRNA (Ambion) by lipofectamine-2000 (Invitrogen) using standard protocols. 72
hours post-transfection, iodide ( 125 I) uptake assays were performed to assess NIS function as described previously (6) . Relative iodide uptake was corrected for protein concentration as measured by the Bradford assay.
Thyroid function tests
Total T 4 and total T 3 in serum of WT and PBF-Tg mice were measured after centrifugation of clotted blood samples using RIA kits (MP Biomedicals). Mouse serum TSH concentrations were determined by the laboratory of Prof Samuel Refetoff (University of Chicago, USA). Details of this assay have been published (20) .
Human thyroid samples
Collection of thyroid samples was in accordance with approval of the Local
Research Ethics committee, and subjects gave informed written consent. Normal thyroid was obtained from the contralateral lobe at the time of surgery.
Statistics
Data are displayed as mean ± SEM. All statistical tests were performed with the 2- 
Results
A murine model of thyroid-targeted PBF induction
To investigate the physiological effect of enhanced PBF expression within thyroid follicular epithelial cells, we constructed a FVB/N transgenic line with targeted expression of PBF driven by the bovine thyroglobulin promoter (Fig. 1A) . Real-time PCR-based zygosity assays indicated that a single copy of the Tg-PBF-HA transgene had integrated into the genomic DNA of the founder mouse and in G1 hemizygotes ( Supplementary Fig. S2 ). Quantification of PBF transgene expression in PBF-Tg thyroids showed an ~7-fold increase relative to endogenous PBF protein levels in wild-type (WT) thyroids (Fig. 1B) . There was no significant expression of the PBF transgene in other major organs examined, including the liver, kidney and spleen ( Supplementary Fig. S3 ). Immunohistochemistry using an anti-HA antibody revealed intense brown staining of the HA-tagged transgene in thyroid follicular epithelial cells, where it was predominantly localised within the cytoplasm (Fig. 1C) .
Male PBF-Tg mice showed no significant change in body weight compared with WT litter-mates up to 10 weeks (Fig. 1D ). In contrast, there was a slight increase in body weight of female PBF-Tg mice at both 7 (13.4% weight gain, P < 0.0001) and 10 (5.5% weight gain, P = 0.04) weeks of age compared to female WT mice. Survival was non-significantly decreased in PBF-Tg mice ( 
PBF-Tg mice show enlarged thyroid glands and altered follicular structure
The most striking phenotype of PBF-Tg mice was an increase in thyroid size and weight. PBF-Tg thyroid glands were 1.7-fold heavier than those of WT litter-mates by 6-7 weeks, and up to 3.2 times heavier by 52 weeks ( Fig. 2A and Supplementary Fig.   S4 ). At 52 weeks of age, the mean thyroid weight of PBF-Tg mice was 10.0 ± 0.6 mg compared with 3.26 ± 0.13 mg for WT mice. Increased thyroid size persisted to 78 weeks ( Fig. 2A) . Interestingly, thyroid glands from female PBF-Tg mice were significantly larger than those of male PBF-Tg littermates at 52 weeks of age (38.5% weight difference, P = 0.0045, Supplementary Fig. S4C ). Critically, the penetrance of increased thyroid weight in PBF-Tg mice was 100%, with all transgenic mice demonstrating markedly enlarged thyroid glands (n = 213). In addition, the thyroid glands of transgenic mice had a superficially nodular appearance on macroscopic evaluation (Fig. 2B ).
To examine mouse thyroid glands microscopically, we performed H&E staining on sections from PBF-Tg and WT mice. Composite images of complete thyroid lobes from PBF-Tg and WT mice demonstrated that the increased size of PBF-Tg thyroids (3-4 mm compared with 2 mm overall length, respectively, Fig. 2C ) might be due to an increased follicular diameter (Fig. 2D) . To quantify this structural difference, we measured the diameter of >3000 follicles in PBF-Tg and WT mice at 26 weeks of age (N = 5 PBF-Tg and 7 WT mice; Fig. 2E ). WT mice had an increased frequency of smaller diameter follicles of <50 μm diameter (P < 0.0001 compared with PBF-Tg).
In contrast, transgenic mice showed a greater preponderance of follicles which exceeded 50 μm diameter than WT (50-100 μm, P = 0.0027; 100-150 μm, P < 
Thyroid-specific over-expression of PBF induces hyperplastic lesions
PBF has previously been shown to induce subcutaneous tumours in nude mice (8) .We therefore examined thyroid morphology at 26, 52 and 78 weeks of age ( 
Thyroid function and gene expression responses to targeted PBF expression
We next investigated thyroid function in response to transgene expression in 6-7 week old PBF-Tg and WT mice by determining serum levels of total triiodothyronine (T3), thyroxine (T4) and TSH. Serum TSH levels were not elevated in either male or female PBF-Tg mice compared to sex-matched WT mice ( Given that TSHR showed dysregulation, we next examined the mRNA expression of 4 further critical thyroid genes (Fig. 4E) . Whilst PTTG has previously been shown to stimulate PBF expression in vitro (8) , there was no reciprocal relationship in vivo, with PTTG mRNA expression unaffected by PBF over-expression (Fig. 4E) .
Thyroglobulin (Tg), thyroid transcription factor 1 (TTF1) and paired box gene 8 (PAX8) expression were also similar in PBF-Tg and WT mice. However, mRNA expression of the sodium iodide symporter NIS was repressed by ~50% in age and sex-matched PBF-Tg mice compared with WT ( Fig. 4E , P = 0.0004). Assessment of NIS immunostaining in thyroid sections revealed a heterogeneity of NIS expression across whole thyroid lobes ( Supplementary Fig. S8 ), but with an overall reduction in NIS protein expression in PBF-Tg mice compared to WT (Fig. 4F) .
PBF represses sodium iodide symporter function in vivo
We have previously reported that PBF inhibits iodide uptake in vitro (2, 6) . Given that PBF-Tg mice showed repressed NIS mRNA and protein expression, we examined NIS function in our transgenic mouse model. We thus performed primary cultures of thyroid cells from age and sex-matched PBF-Tg and WT mice, and performed 125 I uptake assays after 7 days of culture ( 
PBF over-expression induces thyroid cell proliferation in vivo
Because thyroid cell growth is regulated by a series of well described kinase pathways which are frequently disrupted in neoplasia, we next investigated expression of proteins involved in the mitogen activated protein kinase (MAPK) and Fig. 5E and Supplementary   Fig. S10B-D) . Altogether, these results show that PBF over-expression results in increased thyroid cell proliferation in vivo, which is associated with activation of the Akt signalling pathway, as well as increased TSHR.
PBF and NIS expression and function in human MNG
PBF has previously been shown to be increased in differentiated thyroid cancer (8), but has not been examined in thyroid hyperplasia. Given that PBF induced goitre formation in our murine model, we next assessed PBF mRNA and protein expression in human MNG (Fig. 6) . PBF mRNA was increased 2.2 ± 0.3-fold, with scatter plot analysis showing that PBF mRNA expression was up to 5.6-fold higher in MNG than in normal thyroid (Fig. 6A) . Protein expression was similarly induced in MNG 
In contrast to PBF and TSHR, NIS mRNA expression was significantly reduced in MNG (38% reduction, P = 0.002) compared with normal thyroid (Fig. 6C) . Since we have shown in the PBF-Tg mouse that PBF reduces NIS expression, potential associations between these two genes in human MNG were examined. A significant negative correlation between PBF and NIS mRNA expression was apparent in MNG specimens (Fig. 6D , r s = 0.39, P = 0.05).
Finally, to investigate whether over-expression of PBF in human thyroid hyperplasia and neoplasia might represent a therapeutic target, we performed primary culture of normal human thyrocytes, and investigated the outcome of manipulating PBF expression on radioiodide uptake. As in murine cultures, siRNA treatment resulted in repressed PBF expression in human thyrocytes (Fig. 6E) , which was associated with a significant increase in NIS mRNA expression by 2.1 ± 0.35-fold (P = 0.02) at 72 hours post-transfection (Fig. 6F) . By contrast, there was no significant change in TSHR mRNA expression coincident with NIS upregulation ( Supplementary   Fig. S11 ). Crucially, however, in comparison to using scrambled siRNA, targeted repression of endogenous PBF expression in human thyrocytes was associated with a significant gain in radioiodide uptake by 2.0 ± 0.14-fold ( 
Discussion
The mechanisms governing thyroid cell growth in hyperplasia and neoplasia remain to be fully defined, despite recent progress with well characterised oncogenes such as BRAF (21, 22) . Our current study indicates that the relatively uncharacterised gene PBF should be considered a new aetiological factor in the thyroid, as well as a novel therapeutic target.
A possible role for PBF in tumourigenesis was highlighted by previous data showing that subcutaneous expression of murine fibroblasts over-expressing PBF induced high-grade malignant tumour formation in athymic nude mice (8) . To gain insights into the wider role of PBF in thyroid disease, we constructed a PBF-Tg transgenic mouse model using the bovine thyroglobulin promoter to mediate thyroidspecific PBF over-expression. In contrast to our previous subcutaneous study, thyroid through negative feedback at the anterior pituitary. Surprisingly, thyroid growth in the PBF-Tg mouse was not stimulated by elevated serum TSH levels. These results are in sharp contrast to the BRAF V600E mouse which had similar enlargement of the thyroid gland but was associated with an 80-fold increase in TSH levels in 5-week old mice (22) . Instead, gross enlargement of the PBF-Tg mouse thyroid was associated with increased TSHR expression and Akt activation. The precise mechanism by which PBF induces TSHR and Akt is the subject of further work, and it would be interesting in future long-term studies to place PBF-Tg mice on a thyroxine-supplemented diet to suppress TSH, thereby investigating the extent to which goitrogenesis is mediated via the TSH-TSHR axis.
Most activities of the TSHR are mediated through the Gαs protein, which activates the adenylyl cyclase/cAMP cascade (25) . Recent studies have also shown that TSH can stimulate Akt phosphorylation in rat FRTL5 (26) and PCCL3 cells (27, 28) , presumably through coupling to Gβγ dimers and subsequent PI3K activation (28).
These observations would suggest that PBF induction of TSHR might directly confer activation of PI3K/Akt signalling to promote thyroid cell proliferation in vivo. The mechanism of PBF upregulation in human MNG is unknown. However, nodular thyroid disease is markedly more common in females than males (29), and we recently demonstrated in a separate study that PBF is oestrogen-regulated (11) . PBF expression in transgenic PBF-Tg mice was under the control of the thyroglobulin promoter, and hence relatively immune to the effects of oestrogen. We did however observe significantly larger thyroid glands in female PBF-Tg mice compared to male littermates at 52 weeks of age, which might imply that oestrogen has a role in controlling PBF's ability to induce thyroid growth. Recently it was shown that circulating oestrogen can regulate thyroid cell proliferation in Pten L/L ;TPO-Cre mice, but not in WT mice (30) . These findings raise the possibility that PBF over-expression to activate PI3K/Akt signalling might be a contributory factor in increasing the susceptibility of females to thyroid disease. It would therefore be interesting to Radioiodine is central to the treatment of thyroid cancer and toxic nodular hyperthyroidism. It is also increasingly used as first line therapy in Graves' disease (31) and to induce shrinkage of benign goitres (32) . Our murine data provide an important validation of our earlier in vitro observations that PBF is a critical regulator of both NIS expression and function (2, 6) . Mice with targeted over-expression of PBF demonstrated a 70% repression of iodide uptake in primary thyroid cultures. As we observed a ~50% inhibition of NIS mRNA expression in PBF-Tg thyroids compared to WT controls, repressed iodide uptake in PBF-Tg mice cultures may also reflect altered subcellular localisation of NIS (6) . Whilst two recent studies have implicated PI3K/Akt signalling in NIS inhibition (28, 33) , the exact mechanism for PBF-induced NIS mRNA repression remains to be fully clarified.
In MNG, NIS expression is heterogeneous, but is generally increased in hyperfunctioning goitres and low in those that are non-toxic (34) (35) (36) (37) . Our data of reduced NIS expression in MNG are therefore in keeping with those in the literature.
Indeed, the observed phenotype is similar to that of cold thyroid nodules that have reduced NIS mRNA levels and show reduced iodide uptake on scintiscan (35).
Importantly, we were able to demonstrate a significant correlation between PBF and NIS mRNA expression in MNG, which further emphasises the functional interaction between these two genes in vivo. In addition, we were able to demonstrate that NIS expression was heterogeneous throughout the thyroid lobes of PBF-Tg mice, mirroring the typical non-uniformity of radioiodine uptake in human MNG. It will be important to investigate in future studies whether specific regions of high PBF expression in human MNG represent thyroidal regions of lowered radioiodine uptake.
Of central importance to the current investigation is the observation that we were 
In summary, we present evidence that the relatively uncharacterised protooncogene PBF has specific relevance to thyroid cell growth. As well as inducing thyroid cell proliferation and hence goitre in vivo, PBF represses the central therapeutic avenue for thyroid hyperplasia and neoplasia. Thus, in addition to its established role in thyroid cancer, PBF now needs to be further appraised as a critical gene in the aetiology and treatment of thyroid disease as a whole.
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